Canopy Growth Corp
No SEC Form 4 filings for $CGC in the last 30 days.
See all $CGC insider activity →Guardian Capital LP said it completed the merger of the Guardian i3 Global Quality Growth ETF into the Guardian i3 Global Core Equity Fund. According to the company, ETF series units were exchanged on Aug. 14 and the merged fund’s units were delisted from the Toronto Stock Exchange. CGC shares were last up $0.03 at $67.97.
Curaleaf launched an unsolicited offer to buy Aurora Cannabis for $272 million, or $4 per share, about a 45% premium to Aurora’s 30-day VWAP, aiming for about $1.5 billion revenue, $350 million adjusted EBITDA, and $40 million annual cost synergies. The article also discusses whether Canopy Growth could be a future acquisition target, citing its turnaround and global medical cannabis platform.
Canopy Growth says its Kincardine, Ontario cultivation site received renewed EU-GMP certification from Germany’s Regierungspräsidium Tübingen. The company links the recertification to supplying EU flower from Canada and expanding its EU portfolio after acquiring MTL Cannabis. For Q1 FY2027, Canopy reported $81.2M net revenue, with 22% ($17.6M) from Germany.
Over the past 7 days, alphai's AI scored 9 news stories mentioning CGC (Canopy Growth Corp). Coverage has skewed bullish: 6 bullish, 3 neutral, and 0 bearish.
Recent CGC coverage spans regulation, financial news and corporate actions.
ETF series merger and delisting should be mostly operational, with limited fundamental impact but potential short-term trading/liquidity effects for CGC-related ETF holders.
This is more speculative than factual, but it can still drive sentiment and options activity if investors treat it as credible takeover chatter.
EU-GMP recertification reduces regulatory supply risk for Canopy’s Canada-to-Germany medical cannabis channel and supports revenue continuity in Germany.
Improving net cash and a shift toward medical cannabis are supportive, but the article stresses the turnaround is incomplete and still loss-making.
The call provides fresh operating datapoints (revenue, margins, losses) plus forward-looking execution milestones (EU GMP timing, UK shipments) that can shift near-term valuation and risk perception.
alphai scores every news story that mentions CGC with an AI model for sentiment and relevance, and aggregates insider trades from Canopy Growth Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Guardian Capital LP said it completed the merger of the Guardian i3 Global Quality Growth ETF into the Guardian i3 Global Core Equity Fund. According to the company, ETF series units were exchanged on Aug. 14 and the merged fund’s units were delisted from the Toronto Stock Exchange. CGC shares were last up $0.03 at $67.97.
1 min readCuraleaf launched an unsolicited offer to buy Aurora Cannabis for $272 million, or $4 per share, about a 45% premium to Aurora’s 30-day VWAP, aiming for about $1.5 billion revenue, $350 million adjusted EBITDA, and $40 million annual cost synergies. The article also discusses whether Canopy Growth could be a future acquisition target, citing its turnaround and global medical cannabis platform.
4 min readCanopy Growth says its Kincardine, Ontario cultivation site received renewed EU-GMP certification from Germany’s Regierungspräsidium Tübingen. The company links the recertification to supplying EU flower from Canada and expanding its EU portfolio after acquiring MTL Cannabis. For Q1 FY2027, Canopy reported $81.2M net revenue, with 22% ($17.6M) from Germany.
4 min readCanopy Growth (NASDAQ: CGC) says its balance sheet improved after a major recapitalization that reduced debt. For fiscal 2026 ended June 30, it reported about $131.3 million in net cash. The article cites 27% Q4 revenue growth in Canadian medical cannabis and 68% in international medical cannabis, while noting ongoing losses and competitive risks.
7 min readCanopy Growth (CGC) reported Q1 fiscal 2027 net revenue of $81.2 million, up 13% year over year, driven by growth across segments and MTL Cannabis integration. Adjusted gross margin rose to 31% and adjusted EBITDA loss narrowed to $3.2 million. Cash was $337 million at June 30, 2026. Management expects full-year revenue growth and cited a 29% Veterans Affairs Canada reimbursement-rate reduction.
7 min readCanopy Growth said its Kincardine, Ontario cultivation facility received renewed EU Good Manufacturing Practice certification, allowing continued supply of Canadian-grown cannabis to European medical markets. The company links the facility to its EU GMP operation in Germany and reported a 10% year-over-year rise in international cannabis net revenue in Q1 fiscal 2027, with plans to expand its flower portfolio.
2 min readCanopy Growth (TSX: WEED, Nasdaq: CGC) said its Kincardine, Ontario cultivation facility received renewed EU GMP certification from Regierungspräsidium Tübingen. The renewal allows continued supply of Canadian-grown EU GMP cannabis flower to European medical markets. The company cited growth in Europe, including a 10% year-over-year rise in international cannabis net revenue in Q1 fiscal 2027.
3 min readCanopy Growth (TSX: WEED, Nasdaq: CGC) said its Kincardine, Ontario cultivation facility received renewed EU GMP certification from Regierungspräsidium Tübingen Leitstelle Arzneimittelüberwachung Baden-Württemberg. The renewal allows continued supply of Canadian-grown EU GMP cannabis flower to European medical markets. The company cited a 10% year-over-year increase in international cannabis net revenue in Q1 fiscal 2027.
2 min readCanopy Growth said its Ontario facility received renewed EU GMP certification, according to the company. The update relates to regulatory compliance for manufacturing, which can affect its ability to supply products to the EU market. Canopy Growth’s stock in Toronto traded around 1.380 CAD, down 2.13% on the day.
1 min readCanopy Growth (NASDAQ: CGC) says it has simplified operations, reduced expenses, exited BioSteel, and completed its MTL Cannabis acquisition. The company reported about $131.3M net cash at fiscal 2026 end (June 30) after a recapitalization. It cited 27% Q4 growth in Canadian medical cannabis revenue and 68% international medical growth, while noting ongoing losses and U.S. regulatory risk.
7 min read
